Journal of Clinical Endocrinology & Metabolism, Vol 56, 113-120, Copyright © 1983 by Endocrine Society

ARTICLES

Characterization of the cytosol androgen receptor of the human prostate

DM Wilbert, JE Griffin and JD Wilson

Direct measurement of the binding of endogenous androgens to the androgen receptor of human tissues has not been possible because of contamination of tissue with traces of plasma proteins, such as testosterone-binding globulin (TeBG), that contain more androgen- binding capacity than does the receptor itself. Molybdate is known to stabilize the 8-9S forms of other steroid hormone receptors. We took advantage of this phenomenon to characterize the androgen receptor of hyperplastic prostates removed at surgery, using sucrose density gradient centrifugation in a vertical rotor. In 10 mM sodium molybdate, the androgen receptor sediments as a distinct 9.2 +/- 0.5S moiety, easily separable from TeBG. Unlike TeBG, the 9S receptor is not removed by absorption with Concanavalin A. [3H]Dihydrotestosterone (3H-labeled 17 beta-hydroxy-5-alpha-androstan-3-one) binding to the 9S receptor is not removed by absorption with Concanavalin A. [3H]Dihydrotestosterone (3H-labeled 17 beta-hydroxy-5 alpha-androstan-3-one) binding to the 9S receptor is not competed for by excess triamcinolone acetonide (9 alpha- fluoro-11 beta, 16 alpha, 17 alpha, 21-tetrahydroxypregna-1,4-diene- 3,20-dione cyclic 16,17-acetonide) or promegestone (17,21-dimethyl-19- non-pregna-4,9-diene-3,-20-dione), which are known to bind to the progestin receptor. In contrast, [3H]methyltrienolone (3H-labeled 17 beta-hydroxy-17 alpha-methyl-estra-4,9,11-trien-3-one) binds to both androgen and progestin receptors, and consequently, the binding of this ligand to the androgen receptor was assessed in the presence of a 500- fold excess of triamcinolone acetonide. The amounts of 9S binding (7.8 and 5.8 fmol/mg protein) are similar for dihydrotestosterone and methyltrienolone. The amount of 9S binding of testosterone to the receptor was also similar to that of dihydrotestosterone, but the affinity of testosterone for the 9S receptor was only a fifth or less of that for dihydrotestosterone. The observation that testosterone binds less avidly than dihydrotestosterone to the receptor may explain the role of dihydrotestosterone formation in androgen physiology.

This article has been cited by other articles:

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis SRD5A2 Gene Polymorphisms and the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 618 - 624. [Abstract] [Full Text] [PDF]

				T. G. Söderström, C. Bjelfman, E. Brekkan, B. Ask, L. Egevad, B. J. Norlén, and A. Rane Messenger Ribonucleic Acid Levels of Steroid 5{{alpha}}-Reductase 2 in Human Prostate Predict the Enzyme Activity J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 855 - 858. [Abstract] [Full Text]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]

				B. A. Foster and G. R. Cunha Efficacy of Various Natural and Synthetic Androgens to Induce Ductal Branching Morphogenesis in the Developing Anterior Rat Prostate Endocrinology, January 1, 1999; 140(1): 318 - 328. [Abstract] [Full Text]

				R. S. Rittmaster Finasteride N. Engl. J. Med., January 13, 1994; 330(2): 120 - 125. [Full Text]